# NCT04471727 (NCT04471727)

> A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04471727
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Conditions: Small-Cell Lung Cancer; Neuroendocrine Carcinoma
- Interventions: Gocatamig; Atezolizumab; Ifinatamab Deruxtecan (I-DXd)
- Enrollment: 232
- Primary outcome: Percentage of participants who experience an adverse event
- Primary outcome: Percentage of participants who discontinue due to an adverse event
- Primary outcome: Number of participants with dose limiting toxicity (DLT) following treatment with HPN328 as monotherapy or in combination with atezolizumab or I-DXd
- Primary outcome: Maximum concentration (Cmax) of Gocatamig
- Primary outcome: Cmax of Atezolizumab
- Primary outcome: Cmax of I-DXd
- Primary outcome: Time to maximum concentration (Tmax) of Gocatamig
- Primary outcome: Tmax of atezolizumab
- Primary outcome: Tmax of I-DXd
- Primary outcome: Area under the concentration-time curve over the dosing interval t (AUCt) of Gocatamig
- Primary outcome: AUCt of atezolizumab
- Primary outcome: AUCt of I-DXd
- Primary outcome: Area under the concentration-time curve extrapolated to infinity (AUCinf) of Gocatamig
- Primary outcome: AUCinf of atezolizumab
- Primary outcome: AUCinf of I-DXd
- Primary outcome: Terminal half-life (t1/2) of Gocatamig
- Primary outcome: t1/2 of atezolizumab
- Primary outcome: t1/2 of I-DXd
- Primary outcome: Single dose clearance (CL) of Gocatamig
- Primary outcome: CL of atezolizumab
- Primary outcome: CL of I-DXd
- Primary outcome: Steady state maximum concentration (Cmax,ss) of Gocatamig
- Primary outcome: Cmax,ss of atezolizumab
- Primary outcome: Cmax,ss of I-DXd
- Primary outcome: Steady state Ctrough (Ctrough,ss) of Gocatamig
- Primary outcome: Ctrough,ss of atezolizumab
- Primary outcome: Ctrough,ss of I-DXd
- Primary outcome: Steady state time to maximum concentration (Tmax,ss) of Gocatamig
- Primary outcome: Tmax,ss of atezolizumab
- Primary outcome: Tmax,ss of I-DXd
- Primary outcome: Area under the steady state concentration-time curve over dosing interval t (AUCt,ss) of Gocatamig
- Primary outcome: AUCt,ss of atezolizumab
- Primary outcome: AUCt,ss of I-DXd
- Primary outcome: Steady state t1/2 (t1/2,ss) of Gocatamig
- Primary outcome: t1/2,ss of Gocatamig with atezolizumab
- Primary outcome: t1/2,ss of IDXd
- Primary outcome: Steady state CL (CL,ss) of Gocatamig
- Primary outcome: CL,ss of Gocatamig with atezolizumab
- Primary outcome: CL,ss of I-DXd
- Primary outcome: Steady state volume of distribution (V,ss) of Gocatamig
- Primary outcome: V,ss of atezolizumab
- Primary outcome: V,ss of I-DXd
- Primary outcome: Steady state accumulation ratio (AC) of Gocatamig
- Primary outcome: AC of atezolizumab
- Primary outcome: AC of I-DXd

## Indexed commentary on NCT04471727 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04471727